While VEGF targeting offers substantial benefits in the treatment of various tumors, it can also lead to a range of adverse effects, such as wound non-healing, HTN, embolism, bleeding, and phlebitis [33,34,35,36], which typically results in treatment discontinuation [37]. This evidence concerns the gene VEGFA and hypertensive disorder.